NXL

Nexalin Technology Inc

5.75

Sep 04 • 4:14 AM ET +0.39 (7.28%)

Healthcare Medical Devices USA Nano NASD

Sep 03, 9:05 AMNexalin secondary analysis of Alzheimer’s trial finds previously unreported ADAS-Cog memory, comprehension and language gains

Peers: AMIX HSCS INBS ITOC XAIR IVF AEMD BJDX VTAK NUWE

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	4.77M
Enterprise Value	3.77M
Income	-8.99M
Sales	0.22M
Book/sh	2.07
Cash/sh	1.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Sep 16, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	21.70
P/B	2.78
P/C	4.77
P/FCF	-
EV/EBITDA	-
EV/Sales	17.15
Quick Ratio	1.10
Current Ratio	1.25
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-14.02
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-29.12% -1.42%
Sales past 3/5Y	-38.88% 4.43%
EPS Y/Y TTM	32.15%
Sales Y/Y TTM	24.22%
EPS Q/Q	-5.30%
Sales Q/Q	-82.77%
Earnings	Jun 03
EPS/Sales Surpr.	- -

Insider Own	17.85%
Insider Trans	0.00%
Inst Own	13.13%
Inst Trans	-3.53%
ROA	-187.89%
ROE	-240.25%
ROIC	-591.60%
Gross Margin	-931.75%
Oper. Margin	-4202.54%
Profit Margin	-4139.38%
SMA20	-35.01%
SMA50	-46.38%
SMA200	-61.94%
Trades

Shs Outstand	0.73M
Shs Float	0.68M
Short Float	1.68%
Short Ratio	1.25
Short Interest	0.01M
52W High	60.00 -90.42%
52W Low	5.24 9.73%
Volatility	15.15% 9.30%
ATR (14)	0.95
RSI (14)	23.47
Beta	4.02
Rel Volume	0.53
Avg Volume	9.10K
Volume	241

Perf Week	-23.33%
Perf Month	-43.39%
Perf Quarter	-63.40%
Perf Half Y	-56.55%
Perf YTD	-65.65%
Perf Year	-77.45%
Perf 3Y	-52.20%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	60.00
Prev Close	5.36
Price	5.75
Change %	7.28%

Sep-03-26 08:30AM	Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study (GlobeNewswire) -13.41%
Aug-27-26 07:25AM	Nexalin Technology Announces Reverse Stock Split (GlobeNewswire) -13.63%
Jun-23-26 08:30AM	Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform (GlobeNewswire)
Jun-16-26 09:15AM	Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life (GlobeNewswire)
Jun-10-26 09:15AM	Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. (GlobeNewswire)
10:00AM	Loading…
Jun-04-26 10:00AM	Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia (GlobeNewswire)
May-21-26 08:30AM	Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury (GlobeNewswire) +19.10%
May-19-26 08:30AM	Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial (GlobeNewswire)
Apr-28-26 09:15AM	Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia (GlobeNewswire) -8.62%
Apr-22-26 09:35AM	Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment (GlobeNewswire) +7.68%
Apr-15-26 10:00AM	Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China (GlobeNewswire) +18.43%
Apr-14-26 08:30AM	Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21 (GlobeNewswire)
Apr-09-26 07:47AM	Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents (GlobeNewswire) +8.57%
Feb-24-26 08:07AM	Nexalin Announces Pivotal HALO Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market (GlobeNewswire) +15.06%
07:50AM	EXCLUSIVE: Penny Stock Nexalin Advances Pivotal Trial Aiming To Tackle Severe Insomnia (Benzinga)
08:18AM	Loading…
Feb-23-26 08:18AM	Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders (GlobeNewswire)
Feb-05-26 08:37AM	Nexalin Launches NeuroCare, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care (GlobeNewswire) +9.15%
08:21AM	EXCLUSIVE: Nexalin Launches AI-Powered Virtual Clinic For Brain Health For Home Settings (Benzinga)
Feb-02-26 08:45AM	Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation (GlobeNewswire)
Jan-23-26 05:15PM	Nexalin Technology Receives Nasdaq Listing Status Notification (GlobeNewswire)
Jan-14-26 09:00AM	Published Peer-Reviewed Study Demonstrates Nexalin's DIFS Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD (GlobeNewswire) +8.12%
Dec-03-25 08:00AM	Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC Neurostimulation Console in Alzheimer's Disease Program (GlobeNewswire)
Dec-02-25 08:00AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 (GlobeNewswire) +5.43%
Nov-18-25 09:00AM	Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity (GlobeNewswire)
Nov-13-25 09:15AM	Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel (GlobeNewswire) -7.14%
Nov-05-25 08:30AM	Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia (GlobeNewswire)
Oct-30-25 08:30AM	Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS Device in Israel (GlobeNewswire)
Oct-21-25 09:00AM	Nexalin's DIFS Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies (GlobeNewswire) -8.33%
Oct-13-25 08:30AM	Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs (GlobeNewswire)
Oct-10-25 08:00AM	Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit (GlobeNewswire) -14.67%
08:30AM	Loading…
Oct-08-25 08:30AM	Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device (GlobeNewswire) +98.25%
Sep-25-25 08:30AM	Nexalin Technology Announces Issuance of U.S. Patent Covering HALO Clarity Device Featuring DIFS Technology (GlobeNewswire) -6.05%
Aug-25-25 09:00AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9 (GlobeNewswire) -18.24%
Aug-01-25 08:30AM	Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives (GlobeNewswire)
May-28-25 10:00AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3 (GlobeNewswire)
May-13-25 08:30AM	Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data (GlobeNewswire)
May-06-25 02:40PM	Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering (GlobeNewswire) -5.26%
May-05-25 08:20AM	Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock (GlobeNewswire) -25.70%
May-01-25 10:30AM	Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback (GlobeNewswire)
Apr-24-25 09:00AM	Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia (GlobeNewswire) +5.71%
Apr-23-25 09:15AM	Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO Clinical Research and Patient Management (GlobeNewswire)
Apr-21-25 08:00AM	Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices (GlobeNewswire)
Apr-14-25 12:30PM	Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS) Technology in Treating Substance Use Disorders (GlobeNewswire)
Apr-02-25 08:30AM	Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial (GlobeNewswire) +5.79%
Mar-26-25 08:30AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 (GlobeNewswire)
Mar-14-25 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +10.26%
Mar-03-25 08:30AM	Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS ) Technology for Opioid and Other Substance Use Disorders (GlobeNewswire) -10.70%
Feb-28-25 08:30AM	Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval (GlobeNewswire)
Feb-26-25 08:30AM	Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board (GlobeNewswire) +7.60%
Feb-18-25 08:30AM	Nexalin Technology Announces UCSD IRB Approval for use of HALO Clarity in Clinical Trials for mTBI and PTSD Treatment (GlobeNewswire)
Feb-10-25 09:00AM	Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition (GlobeNewswire) -5.38%
Feb-03-25 08:30AM	Nexalin's Breakthrough DIFS Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study (GlobeNewswire)
Jan-23-25 11:00AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23 (GlobeNewswire)
Jan-14-25 08:30AM	Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025 (GlobeNewswire) +10.76%
Dec-23-24 10:00AM	Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic (GlobeNewswire)
Nov-26-24 10:00AM	New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market (GlobeNewswire)
Nov-11-24 08:00AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire) -12.11%
Nov-01-24 02:00PM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th (GlobeNewswire) +26.91%
10:34AM	Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
09:00AM	LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-28-24 08:30AM	Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease (GlobeNewswire)
Oct-25-24 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +6.51%
Oct-22-24 02:15PM	Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA (GlobeNewswire) +20.95%
Oct-17-24 08:30AM	New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients (GlobeNewswire) +25.71%
Oct-14-24 08:30AM	Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs (GlobeNewswire) +15.24%
Sep-05-24 09:00AM	Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment (GlobeNewswire) -10.32%
Jul-26-24 09:55AM	Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +5.98%
Jul-18-24 08:30AM	Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery (GlobeNewswire) -7.41%
Jul-01-24 02:45PM	Nexalin Technology Announces Closing of $5.2 Million Public Offering (GlobeNewswire)
06:31AM	The 3 Smartest Penny Stocks to Buy With Your Money Right Now (InvestorPlace)
Jun-28-24 08:31AM	Why Is Nexalin Technology (NXL) Stock Down 35% Today? (InvestorPlace) -42.91%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 09:15PM	Nexalin Technology Announces Pricing of $5.2 Million Public Offering (GlobeNewswire) +8.42%
Jun-26-24 09:00AM	Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal (GlobeNewswire) +20.80%
Jun-20-24 08:30AM	Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia (GlobeNewswire) +5.77%
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-14-24 09:00AM	Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -34.85%
08:21AM	Why Is Nexalin Technology (NXL) Stock Down 29% Today? (InvestorPlace)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 03:00PM	Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) (GlobeNewswire) +125.10%
Jun-06-24 07:00AM	MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies (ACCESSWIRE) +8.67%
Jun-04-24 08:30AM	Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th (GlobeNewswire)
Jun-03-24 08:30AM	FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity Headset Device (GlobeNewswire)
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +7.37%
May-22-24 08:30AM	Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts (GlobeNewswire)
May-13-24 10:54AM	NXL Stock Earnings: Nexalin Technology Reported Results for Q1 2024 (InvestorPlace)
May-09-24 08:30AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23 (GlobeNewswire)
Apr-25-24 10:44AM	Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
Apr-10-24 08:30AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire)
Apr-09-24 08:30AM	Nexalin Technology Accelerates Manufacturing of its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing (GlobeNewswire)
Apr-04-24 01:00PM	Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity , a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device (GlobeNewswire) -10.42%
11:05AM	Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device (News Direct)
Apr-02-24 08:30AM	Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board (GlobeNewswire) +51.05%
Mar-28-24 08:30AM	Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego (GlobeNewswire) +79.49%
Mar-14-24 08:30AM	Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology (GlobeNewswire) +20.00%
Mar-13-24 08:30AM	Nexalin Technology Announces Poster Presentation at State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment (GlobeNewswire) +8.17%
Mar-06-24 08:30AM	Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia (GlobeNewswire) +49.55%
Feb-08-24 08:30AM	Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device (GlobeNewswire)
Jan-23-24 08:30AM	Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System (GlobeNewswire)
Jan-11-24 08:30AM	Nexalin Technology Unveils Next-Generation HALO Clarity (GlobeNewswire) +9.67%

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices help people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

PresidentMr. Mark White

Chief Medical OfficerDr. David Owens M.D.

Executive VP of ClinicalMs. Carolyn Shelton

Co-Founder and Director of Engineering & DevelopmentMr. John Patrick Claude

Chief Financial OfficerMr. Justin Van Fleet CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elson Marilyn	Associate to Affiliate	Sep 10 '25	Proposed Sale	0.02	23,150	403		Sep 10 03:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NXL

Nexalin Technology Inc

Upgrade your Finviz experience